166 related articles for article (PubMed ID: 1683561)
41. Characterization of the CCK-B/gastrin-like receptor in human colon cancer.
Smith JP; Stock EA; Wotring MG; McLaughlin PJ; Zagon IS
Am J Physiol; 1996 Sep; 271(3 Pt 2):R797-805. PubMed ID: 8853405
[TBL] [Abstract][Full Text] [Related]
42. Importance of sulfation of gastrin or cholecystokinin (CCK) on affinity for gastrin and CCK receptors.
Huang SC; Yu DH; Wank SA; Mantey S; Gardner JD; Jensen RT
Peptides; 1989; 10(4):785-9. PubMed ID: 2479932
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally AV
Int J Cancer; 1994 May; 57(4):574-80. PubMed ID: 7910153
[TBL] [Abstract][Full Text] [Related]
44. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer.
Robertson JF; Watson SA; Hardcastle JD
Int J Cancer; 1995 Sep; 63(1):69-75. PubMed ID: 7558455
[TBL] [Abstract][Full Text] [Related]
45. Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer.
Morimoto H; Nio Y; Tsubono M; Tseng CC; Kawabata K; Masai Y; Hayashi H; Baba N; Manabe T; Hosokawa Y
J Surg Oncol; 1993 May; 53(1):47-53. PubMed ID: 8386784
[TBL] [Abstract][Full Text] [Related]
46. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
47. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.
Reubi JC; Schaer JC; Waser B
Cancer Res; 1997 Apr; 57(7):1377-86. PubMed ID: 9102227
[TBL] [Abstract][Full Text] [Related]
48. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.
Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP
J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430
[TBL] [Abstract][Full Text] [Related]
49. CCK-JMV-180 acts as an antagonist of the CCKA receptor in the human IMR-32 neuroblastoma cell line.
Schaeffer P; Prabonnaud V; Roux M; Gully D; Herbert JM
FEBS Lett; 1994 Nov; 354(2):203-6. PubMed ID: 7957924
[TBL] [Abstract][Full Text] [Related]
50. Distinct receptors for cholecystokinin and gastrin on canine fundic D-cells.
DelValle J; Chiba T; Park J; Yamada T
Am J Physiol; 1993 May; 264(5 Pt 1):G811-5. PubMed ID: 8098910
[TBL] [Abstract][Full Text] [Related]
51. High affinity binding of cholecystokinin to small cell lung cancer cells.
Yoder DG; Moody TW
Peptides; 1987; 8(1):103-7. PubMed ID: 3033616
[TBL] [Abstract][Full Text] [Related]
52. Direct demonstration of three different states of the pancreatic cholecystokinin receptor.
Talkad VD; Fortune KP; Pollo DA; Shah GN; Wank SA; Gardner JD
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1868-72. PubMed ID: 8127897
[TBL] [Abstract][Full Text] [Related]
53. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas.
Reubi JC; Waser B
Int J Cancer; 1996 Sep; 67(5):644-7. PubMed ID: 8782652
[TBL] [Abstract][Full Text] [Related]
54. A new CCK analogue differentiates two functionally distinct CCK receptors in rat and mouse pancreatic acini.
Matozaki T; Martinez J; Williams JA
Am J Physiol; 1989 Oct; 257(4 Pt 1):G594-600. PubMed ID: 2478032
[TBL] [Abstract][Full Text] [Related]
55. Molecular heterogeneity of somatostatin analogue BIM-23014C receptors in human breast carcinoma cells using the chemical cross-linking assay.
Prévost G; Lanson M; Thomas F; Veber N; Gonzalez W; Beaupain R; Starzec A; Bogden A
Cancer Res; 1992 Feb; 52(4):843-50. PubMed ID: 1346585
[TBL] [Abstract][Full Text] [Related]
56. Binding of a phenethyl ester analogue of cholecystokinin to the solubilized pancreatic cholecystokinin receptor: use in ligand-affinity chromatography.
Miller LJ; Hadac EM; Gates LK; Gaisano HY
Biochem Biophys Res Commun; 1992 Mar; 183(2):396-404. PubMed ID: 1550549
[TBL] [Abstract][Full Text] [Related]
57. Expression of somatostatin receptors in human pancreatic tumor.
Tang C; Biemond I; Verspaget HW; Offerhaus GJ; Lamers CB
Pancreas; 1998 Jul; 17(1):80-4. PubMed ID: 9667524
[TBL] [Abstract][Full Text] [Related]
58. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
59. Characterization of specific somatostatin binding sites in guinea pig lung.
Barrios V; Fernandez Iriarte MC; Morcillo E; Prieto JC; Arilla E
Regul Pept; 1987 Nov; 19(3-4):149-59. PubMed ID: 2893434
[TBL] [Abstract][Full Text] [Related]
60. Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas.
Tang C; Biemond I; Offerhaus GJ; Verspaget W; Lamers CB
Br J Cancer; 1997; 75(10):1467-73. PubMed ID: 9166939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
